HLB Pharmaceutical Co., Ltd. (KOSDAQ:047920)

Market Cap	248.55B -11.9%
Revenue (ttm)	205.58B +469.5%
Net Income	4.57B +867.2%
EPS	140.00 +310.2%
Shares Out	14.04M
PE Ratio	126.43
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	79,131
Average Volume	141,130
Open	17,700
Previous Close	17,700
Day's Range	17,270 - 17,700
52-Week Range	12,500 - 22,250
Beta	0.39
RSI	50.47
Earnings Date	May 15, 2026

About HLB Pharmaceutical

HLB Pharmaceutical Co., Ltd. researches and develops peptide drugs in South Korea. The company offers skeletal muscle relaxant, tranquilizers, antihistamines, antihypertensive agents, pain relief, antipruritics, astringents, anti-inflammatories, alimentary system drugs, metabolic drugs, ophthalmic agents, local anesthetics, antiarteriosclerotic agents, expectorants, antipyretics, analgesics, antidiabetic drug, chemotherapeutics, peptic ulcer agents, central nervous system drug, antibiotics, digestives, antacids, dental drugs, multivitamins, par...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 047920

Financial Performance

In 2025, HLB Pharmaceutical's revenue was 205.58 billion, an increase of 49.97% compared to the previous year's 137.08 billion. Earnings were 4.57 billion, an increase of 126.35%.